Clinical Trial Update: CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of CMP-001 in combination with nivolumab in advanced melanoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CMP-001
• nivolumab (nivolumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Melanoma, Advanced Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2025-04-02